AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Exploring the Selection of BTKIs in Frontline Therapy
Exploring the considerations for selecting BTKIs in frontline therapy, focusing on toxicity profiles, patient comorbidities, and the tolerability of second-generation BTKIs like Daniel and Calibrietinib. Emphasizing patient-specific factors over efficacy differences, this chapter raises unanswered questions in the field.